Trial Profile
A phase II study of the combination apatinib with VP16 in heavily pre-treated recurrent epithelial ovarian cancer patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2018
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 16 Apr 2018 New trial record